Aspergillus fumigatus, a filamentous fungus, is notorious for causing various infections, especially in immunocompromised individuals.
One critical component of this pathogen is Asp f4, a glycosylated hydrolase enzyme integral to its virulence. Asp f4 plays a significant role in nutrient acquisition, colonization, and invasion of host tissues by breaking down complex carbohydrates.
Clinically, approximately 92% of patients with allergic bronchopulmonary aspergillosis (ABPA) are sensitized to Asp f4, making it a crucial marker for distinguishing ABPA from simple Aspergillus sensitization.
Advanced diagnostic tools like the Basophil Activation Test (BAT) with Asp f4 have shown high sensitivity and specificity, enhancing the accuracy of ABPA diagnosis and improving patient outcomes.
Aspergillus fumigatus is a species of filamentous fungus that plays important ecological roles but can also cause serious infections in humans.
Aspergillus fumigatus is a leading cause of aspergillosis, an infection ranging from allergic reactions to invasive pulmonary disease, particularly affecting immunocompromised individuals.
Early diagnosis, species identification, and appropriate antifungal therapy are crucial for effective treatment.
Aspergillus fumigatus is part of the genus Aspergillus, which includes over 250 species, many of which are pathogenic.
This species is characterized by bluish-green conidial heads and a high thermotolerance, allowing it to thrive in diverse environments, from soil and compost to decaying vegetation. It is highly prevalent due to its resilience and ability to produce numerous secondary metabolites.
A. fumigatus possesses several virulence factors, such as conidial melanin and gliotoxin, which help it evade host defenses.
It can grow at body temperature and survive in the host's nutrient-limited environment, making it a formidable pathogen in immunocompromised patients.
The fungus’ ability to produce ascospores, virulence factors, and its high thermotolerance contribute to its virulence.
Infections by A. fumigatus primarily affect the lungs but can disseminate to other organs, especially in immunocompromised patients.
The central nervous system is another common site highly affected by A. fumigatus. [13.]
Conditions include invasive aspergillosis (IA), allergic bronchopulmonary aspergillosis (ABPA), and chronic pulmonary aspergillosis. IA has a high fatality rate and is particularly severe in patients with weakened immune systems.
Acute invasive aspergillosis is a serious infection in immunocompromised patients, characterized by rapid progression, often resulting in high fatality rates.
In contrast, chronic Aspergillus infections typically affect patients with some degree of immune suppression and underlying lung diseases like chronic obstructive pulmonary disease (COPD), as well as those on long-term corticosteroids. It progresses slowly, leading to lung tissue damage or sinus problems over time.
Allergic aspergillosis, including Allergic Bronchopulmonary Aspergillosis (ABPA) and Allergic Fungal Sinusitis, are caused by type 1 or type 3 hypersensitivity reactions. ABPA, a pulmonary disease caused by hypersensitivity reactions to Aspergillus fumigatus allergens, commonly occurs in asthmatic and cystic fibrosis patients and causes bronchial obstruction, productive cough, wheezing, chest pain, fever, and malaise.
Allergic fungal sinusitis causes inflammation and obstruction without tissue invasion.
Accurate diagnosis involves a combination of morphological and genetic analyses, with galactomannan and (1,3)-β-D-glucan assays being commonly used. Certain antigens and virulence factors such as A. fumigatus Asp f 4 can also be tested.
Voriconazole is the preferred treatment for IA, supported by guidelines from the Infectious Diseases Society of America. [15.] Timely initiation of antifungal therapy is critical for improving patient outcomes.
Virulence factors of Aspergillus species include:
Biofilms protect Aspergillus from host defenses and antifungal treatments, promoting persistent and chronic infections, especially in immune-compromised individuals. [10.]
Lipases degrade lipids, aiding in nutrient acquisition and tissue invasion by breaking down host cell membranes. [10.]
α-Amylase breaks down carbohydrates, providing energy and aiding in colonization of host tissues. [10.]
Pectinases degrade pectin, a polysaccharide found in plant cell walls, facilitating the invasion of plant-derived substrates. [10.]
Proteinases degrade proteins, helping the fungus to invade host tissues and evade immune responses. [10.]
Phospholipases break down phospholipids in cell membranes, aiding in host cell lysis and tissue penetration. [10.]
Haemolysins lyse red blood cells, releasing iron and other nutrients vital for fungal growth and survival in the host. [10.]
Catalases (Cat1p and Cat2p) and superoxide dismutases (MnSOD and Cu, ZnSOD) produced by Aspergillus neutralize the immune system’s offenses. [12.]
These virulence factors confuse and impede the immune response, while promoting cell invasion and death. [12.]
Asp f 4 is part of a family of ribotoxins produced by Aspergillus species. They are potent inhibitors of protein synthesis in eukaryotic cells, as well as potent stimulators of allergenicity. The family of ribotoxins includes mitogillin, restrictocin, and α-sarcin, and Asp f1 to Asp f23. [6.]
A. fumigatus Asp f4 is a glycosylated hydrolase enzyme. It is considered a somatic protein, meaning that it’s part of the fungal cell wall, rather than being secreted. [2.]
These types of enzymes catalyze the hydrolysis of glycosidic bonds in complex sugars. This enzymatic activity is crucial for breaking down carbohydrate structures, which can be integral to the fungal cell wall or derived from the host during infection.
Approximately 92% of patients with allergic bronchopulmonary aspergillosis (ABPA) are sensitized to Asp f4, making it a significant marker for ABPA. [5.] Sensitization rates to Asp f4 are notably higher in ABPA patients compared to those with A. fumigatus-sensitized asthma.
Additionally, the presence of Asp f4 along with other biomarkers such as Asp f3 and Asp f6 can indicate a more complex immune response to Aspergillus in ABPA. [2.]
Recombinant Asp f4 has been shown to provoke immediate skin reactions specifically in patients with ABPA, indicating its role in distinguishing ABPA from simple fungal sensitization. [5.]
Asp f4 blood testing is used to improve the accuracy of ABPA diagnosis. Testing for specific IgE antibodies to Asp f4 helps distinguish true A. fumigatus sensitization from cross-reactivity with other fungi. [14.]
The main diagnostic criteria for ABPA rely on evaluating immunoglobulin (Ig) E and IgG responses to AF extracts, although these cannot discriminate AF-sensitization from ABPA. [9.]
The Basophil Activation Test (BAT) is a functional assay that measures the activation of basophils, a type of white blood cell, in response to specific allergens.
BAT with A. fumigatus Asp f 4 has shown promising results in differentiating ABPA patients from those with Aspergillus sensitization alone.
The test involves incubating patient's blood samples with A. fumigatus Asp f 4 and measuring the expression of activation markers on basophils using flow cytometry.
The level of basophil activation is quantified by comparing the percentage of activated basophils in the presence of the allergen to those in a control sample without the allergen. This ratio is known as the Stimulation Index (SI).
Compared to traditional tests, BAT with A. fumigatus Asp f 4 has demonstrated higher sensitivity and specificity in diagnosing ABPA. [9.]
Often, blood tests are run to assess for antibodies against the infectious agent A. fumigatus, as well as antibodies against certain virulence factors including Aspergillus fumigatus Asp f 4.
Sputum or bronchoalveolar lavage may also be assessed for the presence of Aspergillus fumigatus.
Blood tests typically require a venipuncture.
While special preparation may not be required, it is essential to consult with the ordering provider prior to sample collection.
A. fumigatus Asp f 4 is a virulence factor associated with infection by the A. fumigatus fungus. Ideal levels are undetectable, or extremely low, in the absence of symptoms.
The presence of symptoms, even with extremely low levels on testing, may signify the need for further assessment including additional attesting for the presence of other molds, fungi, mycotoxins, or infectious agents.
Elevated levels of A. fumigatus may indicate an allergic sensitization, or an active infection. An infection signals a need for eradication of the A. fumigatus organism; additional assessment for the presence of co-infections may be warranted.
An individual with elevated levels of this biomarker may need additional assessment of immune function and may require additional immune support.
Click here to compare testing options and order tests for Aspergillus fumigatus levels.
[1.] Arruda LK, Platts-Mills TA, Fox JW, Chapman MD. Aspergillus fumigatus allergen I, a major IgE-binding protein, is a member of the mitogillin family of cytotoxins. J Exp Med. 1990 Nov 1;172(5):1529-32. doi: 10.1084/jem.172.5.1529. PMID: 2230656; PMCID: PMC2188668.
[2.] Carsin A, Romain T, Ranque S, Reynaud-Gaubert M, Dubus JC, Mège JL, Vitte J. Aspergillus fumigatus in cystic fibrosis: An update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis. Allergy. 2017 Nov;72(11):1632-1642. doi: 10.1111/all.13204. Epub 2017 Jun 9. PMID: 28513848.
[3.] Davies G, Singh O, Prattes J, Hoenigl M, Sheppard PW, Thornton CR. Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology. J Fungi (Basel). 2020 Dec 31;7(1):19. doi: 10.3390/jof7010019. PMID: 33396482; PMCID: PMC7823411.
[4.] Fukutomi Y, Taniguchi M. Sensitization to fungal allergens: Resolved and unresolved issues. Allergology International. 2015;64(4):321-331. doi:https://doi.org/10.1016/j.alit.2015.05.007
[5.] Hemmann S, Menz G, Ismail C, Blaser K, Crameri R. Skin test reactivity to 2 recombinant Aspergillus fumigatus allergens in A fumigatus-sensitized asthmatic subjects allows diagnostic separation of allergic bronchopulmonary aspergillosis from fungal sensitization. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):601-7. doi: 10.1016/s0091-6749(99)70330-1. PMID: 10482834.
[6.] Kurup VP, Banerjee B, Murali PS, Greenberger PA, Krishnan M, Hari V, Fink JN. Immunodominant peptide epitopes of allergen, Asp f 1 from the fungus Aspergillus fumigatus. Peptides. 1998;19(9):1469-77. doi: 10.1016/s0196-9781(98)00113-2. PMID: 9864052.
[7.] Kuwabara K, Hirose M, Kato K, Yokoi T, Shiga M, Kondo R, Nakamura M, Matsunaga K, Horiguchi T. Serological analysis of sensitization in allergic bronchopulmonary aspergillosis: a study on allergen components and interspecies relationships. J Asthma. 2020 Jun;57(6):610-617. doi: 10.1080/02770903.2019.1599387. Epub 2019 Apr 4. PMID: 30943819.
[8.] Luo W, Hu H, Wu Z, Wei N, Huang H, Zheng P, Liu Y, Sun B. Molecular allergen sensitization of Aspergillus fumigatus between allergic bronchopulmonary aspergillosis and A fumigatus-sensitized asthma in Guangzhou, Southern China. J Clin Lab Anal. 2020 Oct;34(10):e23448. doi: 10.1002/jcla.23448. Epub 2020 Jul 2. PMID: 32614101; PMCID: PMC7595924.
[9.] Michel M, Youssouf Sereme, Farid Mankouri, et al. Basophil Activation Test With Aspergillus Molecules: The Case for ABPA. Frontiers in allergy. 2022;3. doi:https://doi.org/10.3389/falgy.2022.898731
[10.] Raksha, Singh G, Urhekar AD. Virulence Factors Detection in Aspergillus Isolates from Clinical and Environmental Samples. J Clin Diagn Res. 2017 Jul;11(7):DC13-DC18. doi: 10.7860/JCDR/2017/24055.10211. Epub 2017 Jul 1. PMID: 28892890; PMCID: PMC5583800.
[11.] Raval KM, Ghormade V, Rajamohanan PR, Choudhary H, Rudramurthy SM, Chakrabarti A, Paknikar K. Development of a nano-gold immunodiagnostic assay for rapid on-site detection of invasive aspergillosis. J Med Microbiol. 2019 Sep;68(9):1341-1352. doi: 10.1099/jmm.0.001040. PMID: 31355743.
[12.] Rementeria A, López-Molina N, Ludwig A, Vivanco AB, Bikandi J, Pontón J, Garaizar J. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol. 2005 Mar;22(1):1-23. doi: 10.1016/s1130-1406(05)70001-2. PMID: 15813678.
[13.] Sugui JA, Kwon-Chung KJ, Juvvadi PR, Latgé JP, Steinbach WJ. Aspergillus fumigatus and related species. Cold Spring Harb Perspect Med. 2014 Nov 6;5(2):a019786. doi: 10.1101/cshperspect.a019786. PMID: 25377144; PMCID: PMC4315914.
[14.] Tanimoto H, Fukutomi Y, Yasueda H, Takeuchi Y, Saito A, Watai K, Sekiya K, Tsuburai T, Asano K, Taniguchi M, Akiyama K. Molecular-based allergy diagnosis of allergic bronchopulmonary aspergillosis in Aspergillus fumigatus-sensitized Japanese patients. Clin Exp Allergy. 2015 Dec;45(12):1790-800. doi: 10.1111/cea.12590. Erratum in: Clin Exp Allergy. 2016 Feb;46(2):381. doi: 10.1111/cea.12698. PMID: 26118958.
[15.] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(3):327-360. doi:https://doi.org/10.1086/525258